{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T03:30:44Z","timestamp":1784863844892,"version":"3.55.0"},"reference-count":151,"publisher":"Elsevier","isbn-type":[{"value":"9780323899413","type":"print"}],"license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022]]},"DOI":"10.1016\/bs.ircmb.2021.02.010","type":"book-chapter","created":{"date-parts":[[2021,4,5]],"date-time":"2021-04-05T09:29:34Z","timestamp":1617614974000},"page":"187-220","source":"Crossref","is-referenced-by-count":6,"title":["Lab tests for MPN"],"prefix":"10.1016","member":"78","reference":[{"issue":"6","key":"10.1016\/bs.ircmb.2021.02.010_bb0010","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1002\/ajh.23446","article-title":"Quantification of JAK2V617F mutation by next-generation sequencing technology","volume":"88","author":"Abdelhamid","year":"2013","journal-title":"Am. J. Hematol."},{"issue":"1","key":"10.1016\/bs.ircmb.2021.02.010_bb0015","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0227986","article-title":"Assessment of the clinical utility of four NGS panels in myeloid malignancies. Suggestions for NGS panel choice or design","volume":"15","author":"Aguilera-Diaz","year":"2020","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/bs.ircmb.2021.02.010_bb0020","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1111\/j.1365-2141.2008.07180.x","article-title":"Loss of the JAK2 intramolecular auto-inhibition mechanism is predicted by structural modelling of a novel exon 12 insertion mutation in a case of idiopathic erythrocytosis","volume":"142","author":"Albiero","year":"2008","journal-title":"Br. J. Haematol."},{"issue":"2","key":"10.1016\/bs.ircmb.2021.02.010_bb0025","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1373\/clinchem.2016.262824","article-title":"RT-qPCR and RT-digital PCR: a comparison of different platforms for the evaluation of residual disease in chronic myeloid Leukemia","volume":"63","author":"Alikian","year":"2017","journal-title":"Clin. Chem."},{"issue":"8","key":"10.1016\/bs.ircmb.2021.02.010_bb0030","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2016.75","article-title":"Molecular characterisation of triple negative essential thrombocythaemia patients by platelet analysis and targeted sequencing","volume":"6","author":"Angona","year":"2016","journal-title":"Blood Cancer J."},{"issue":"1","key":"10.1016\/bs.ircmb.2021.02.010_bb0245","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1182\/asheducation-2016.1.534","article-title":"Update from the latest WHO classification of MPNs: a user's manual","volume":"2016","year":"2016","journal-title":"Hematology Am. Soc. Hematol. Educ. Program"},{"key":"10.1016\/bs.ircmb.2021.02.010_bb0035","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/S0140-6736(13)62120-0","article-title":"Chronic myeloid leukaemia","volume":"385","author":"Apperley","year":"2015","journal-title":"Lancet"},{"issue":"20","key":"10.1016\/bs.ircmb.2021.02.010_bb0040","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"issue":"6","key":"10.1016\/bs.ircmb.2021.02.010_bb0045","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1038\/leu.2015.24","article-title":"KIT mutation analysis in mast cell neoplasms: recommendations of the European Competence Network on Mastocytosis","volume":"29","author":"Arock","year":"2015","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/bs.ircmb.2021.02.010_bb0050","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013","volume":"122","author":"Baccarani","year":"2013","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.02.010_bb0055","series-title":"World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues","first-page":"68","article-title":"Myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB, or FGFR1","author":"Bain","year":"2008"},{"issue":"1","key":"10.1016\/bs.ircmb.2021.02.010_bb0060","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/leu.2014.277","article-title":"SRSF2 and U2AF1 mutations in primary myelofibrosis are associated with JAK2 and MPL but not calreticulin mutation and may independently reoccur after allogeneic stem cell transplantation","volume":"29","author":"Bartels","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/bs.ircmb.2021.02.010_bb0065","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)71142-9","article-title":"Acquired mutation of thetyrosine kinase JAK2 in human myeloproliferative disorders","volume":"365","author":"Baxter","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/bs.ircmb.2021.02.010_bb0070","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1182\/blood-2008-01-131664","article-title":"MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort","volume":"112","author":"Beer","year":"2008","journal-title":"Blood"},{"issue":"1","key":"10.1016\/bs.ircmb.2021.02.010_bb0075","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/bjh.12075","article-title":"Molecular diagnosis of the myeloproliferative neoplasms: UK guidelines for the detection of JAK2 V617F and other relevant mutations","volume":"160","author":"Bench","year":"2013","journal-title":"Br. J. Haematol."},{"issue":"4","key":"10.1016\/bs.ircmb.2021.02.010_bb0080","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1002\/ajh.21357","article-title":"Isolated erythrocytosis in V617F negative patients with JAK2 exon 12 mutations: report of a new mutation","volume":"84","author":"Bernardi","year":"2009","journal-title":"Am. J. Hematol."},{"issue":"33","key":"10.1016\/bs.ircmb.2021.02.010_bb0085","doi-asserted-by":"crossref","first-page":"52614","DOI":"10.18632\/oncotarget.10376","article-title":"CALR mutation characterization in myeloproliferative neoplasms","volume":"7","author":"Bilbao-Sieyro","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/bs.ircmb.2021.02.010_bb0090","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1111\/j.1365-2141.2010.08083.x","article-title":"Clinical utility of routine MPL exon 10 analysis in the diagnosis of essential thrombocythaemia and primary myelofibrosis","volume":"149","author":"Boyd","year":"2010","journal-title":"Br. J. Haematol."},{"issue":"11","key":"10.1016\/bs.ircmb.2021.02.010_bb0095","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1182\/blood.V104.11.274.274","article-title":"BCR-ABL levels continue to decrease up to 42 months after commencement of standard dose Imatinib in patients with newly diagnosed chronic phase CML who achieve a major molecular response","volume":"104","author":"Branford","year":"2004","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.02.010_bb0100","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1038\/ng.2413","article-title":"Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis","volume":"44","author":"Busque","year":"2012","journal-title":"Nat. Genet."},{"key":"10.1016\/bs.ircmb.2021.02.010_bb0105","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jmoldx.2010.12.002","article-title":"Nested high-resolution melting curve analysis a highly sensitive, reliable, and simple method for detection of JAK2 exon 12 mutations\u2013clinical relevance in the monitoring of polycythemia","volume":"13","author":"Carillo","year":"2011","journal-title":"J. Mol. Diagn."},{"key":"10.1016\/bs.ircmb.2021.02.010_bb0110","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s00277-014-2232-8","article-title":"Calreticulin mutations in myeloproliferative neoplasms and new methodology for their detection and monitoring","volume":"94","author":"Chi","year":"2015","journal-title":"Ann. Hematol."},{"issue":"1","key":"10.1016\/bs.ircmb.2021.02.010_bb0115","doi-asserted-by":"crossref","first-page":"72","DOI":"10.3343\/alm.2020.40.1.72","article-title":"Performance evaluation of the QXDx BCR-ABL %IS droplet digital PCR assay","volume":"40","author":"Chung","year":"2020","journal-title":"Ann. Lab. Med."},{"issue":"3","key":"10.1016\/bs.ircmb.2021.02.010_bb0120","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.beha.2009.04.001","article-title":"Standardisation of molecular monitoring for chronic myeloid leukaemia","volume":"22","author":"Cross","year":"2009","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"10.1016\/bs.ircmb.2021.02.010_bb0125","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1126\/science.2406902","article-title":"Induction of chronic myelogenousleukemia in mice by the P210bcr\/abl gene of the Philadelphia chromosome","volume":"247","author":"Daley","year":"1990","journal-title":"Science"},{"key":"10.1016\/bs.ircmb.2021.02.010_bb0130","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1182\/blood.V96.10.3343","article-title":"The molecular biology of chronic myeloid leukemia","volume":"96","author":"Deininger","year":"2000","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.02.010_bb0135","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.plabm.2015.12.004","article-title":"Comparative study of different methodologies to detect the JAK2 V617F mutation in chronic BCR-ABL1 negative myeloproliferative neoplasms","volume":"4","author":"Didone","year":"2015","journal-title":"Pract. Lab. Med."},{"key":"10.1016\/bs.ircmb.2021.02.010_bb0140","first-page":"2535","article-title":"Interphase FISH for follow-up of Philadelphia chromosome positive chronic myeloid leukemia treatment","volume":"24","author":"Douet-Guilbert","year":"2004","journal-title":"Anticancer Res"},{"issue":"7","key":"10.1016\/bs.ircmb.2021.02.010_bb0145","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1002\/ajh.24381","article-title":"Monitoring disease burden in chronic myeloid leukemia: past, present, and future","volume":"91","author":"Egan","year":"2016","journal-title":"Am. J. Hematol."},{"key":"10.1016\/bs.ircmb.2021.02.010_bb0150","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.1365-2141.2004.04899.x","article-title":"Results of imatinibmesylate therapy in chronic myelogenousleukemia with variant Philadelphia chromosome","volume":"125","author":"El-Zimaity","year":"2004","journal-title":"Br. J. Haematol."},{"issue":"1\u20132","key":"10.1016\/bs.ircmb.2021.02.010_bb0155","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.cca.2009.07.002","article-title":"Detection of the JAK2 V617F missense mutation by high resolution melting analysis and its validation","volume":"408","author":"Er","year":"2009","journal-title":"Clin. Chim. Acta"},{"issue":"26","key":"10.1016\/bs.ircmb.2021.02.010_bb0160","doi-asserted-by":"crossref","first-page":"6760","DOI":"10.1182\/blood-2011-08-373902","article-title":"HochhausA et al. impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV","volume":"118","author":"Fabarius","year":"2011","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.02.010_bb0165","doi-asserted-by":"crossref","first-page":"207","DOI":"10.7326\/0003-4819-131-3-199908030-00008","article-title":"Chronic myelogenousleukemia: biology and therapy","volume":"131","author":"Faderl","year":"1999","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/bs.ircmb.2021.02.010_bb0170","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1111\/ijlh.12404","article-title":"Real-time PCR and droplet digital PCR: two techniques for detection of the JAK2(V617F) mutation in Philadelphia-negative chronic myeloproliferative neoplasms","volume":"37","author":"Fontanelli","year":"2015","journal-title":"Int. J. Lab. Hematol."},{"issue":"2","key":"10.1016\/bs.ircmb.2021.02.010_bb0175","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/j.1365-2141.2011.08603.x","article-title":"Guidelines for the measurement of BCR-ABL1 transcripts in chronic myeloid leukaemia","volume":"153","author":"Foroni","year":"2011","journal-title":"Br. J. Haematol."},{"issue":"1","key":"10.1016\/bs.ircmb.2021.02.010_bb0180","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jmoldx.2019.08.007","article-title":"Comparison of real-time quantitative PCR and digital droplet PCR for BCR-ABL1 monitoring in patients with chronic myeloid leukemia","volume":"22","author":"Franke","year":"2020","journal-title":"J. Mol. Diagn."},{"key":"10.1016\/bs.ircmb.2021.02.010_bb0185","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.jmoldx.2013.07.006","article-title":"Detection of MPL mutations by a novel allele-specific PCR-based strategy","volume":"15","author":"Furtado","year":"2013","journal-title":"J. Mol. Diagn."},{"issue":"7","key":"10.1016\/bs.ircmb.2021.02.010_bb0190","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1182\/blood-2006-04-015545","article-title":"KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in sistemi mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients","volume":"108","author":"Garcia-Montero","year":"2006","journal-title":"Blood"},{"issue":"5","key":"10.1016\/bs.ircmb.2021.02.010_bb0195","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1002\/ccr3.2720","article-title":"Diagnosis of exon 12-positive polycythemia vera rescued by NGS","volume":"8","author":"Geay","year":"2020","journal-title":"Clin. Case Rep."},{"key":"10.1016\/bs.ircmb.2021.02.010_bb0200","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/j.1751-553X.2008.01118.x","article-title":"Rapid real-time PCR assay for detection of MPL W515L mutation in patients with chronic myeloproliferative disorders","volume":"32","author":"Ghaderi","year":"2010","journal-title":"Int. J. Lab. Hematol."},{"issue":"25","key":"10.1016\/bs.ircmb.2021.02.010_bb0205","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1182\/bloodadvances.2017012229","article-title":"Buccal epithelial cells display somatic, bone marrow-derived CALR mutation","volume":"1","author":"Gilles","year":"2017","journal-title":"Blood Adv."},{"issue":"6","key":"10.1016\/bs.ircmb.2021.02.010_bb0210","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.jmoldx.2013.07.002","article-title":"Laboratory practice guidelines for detecting and reporting JAK2 and MPL mutations in myeloproliferative neoplasms: a report of the Association for Molecular Pathology","volume":"15","author":"Gong","year":"2013","journal-title":"J. Mol. Diagn."},{"key":"10.1016\/bs.ircmb.2021.02.010_bb0215","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1038\/leu.2008.287","article-title":"Five years since the discovery of FIP1L1\u2013PDGFRA: what we have learned about the fusion and other molecularly defined eosinophilias","volume":"22","author":"Gotlib","year":"2008","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/bs.ircmb.2021.02.010_bb0220","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2015.90","article-title":"Validation of the differential prognostic impact of type 1\/type 1-like versus type 2\/type 2-like CALR mutations in myelofibrosis","volume":"5","author":"Guglielmelli","year":"2015","journal-title":"Blood Cancer J."},{"issue":"9","key":"10.1016\/bs.ircmb.2021.02.010_bb0225","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1002\/ajh.24442","article-title":"Prognostic impact of bone marrow fibrosis in primary myelofibrosis. A study of the AGIMM group on 490 patients","volume":"91","author":"Guglielmelli","year":"2016","journal-title":"Am. J. Hematol."},{"key":"10.1016\/bs.ircmb.2021.02.010_bb0230","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.leukres.2017.04.006","article-title":"Recommendations for molecular testing in classical Ph1-neg myeloproliferative disorders-A consensus project of the Italian Society of Hematology","volume":"58","author":"Guglielmelli","year":"2017","journal-title":"Leuk. Res."},{"issue":"12","key":"10.1016\/bs.ircmb.2021.02.010_bb0235","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1038\/sj.leu.2402730","article-title":"Comparison of competitive-nested PCR and real-time PCR in detecting BCR-ABL fusion transcripts in chronic myeloid leukemia patients","volume":"16","author":"Guo","year":"2002","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/bs.ircmb.2021.02.010_bb0240","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1007\/s11899-013-0154-5","article-title":"Acute myeloid leukemia following a myeloproliferative neoplasm: clinical characteristics, genetic features and effects of therapy","volume":"8","author":"Heaney","year":"2013","journal-title":"Curr. Hematol. Malig. Rep."},{"issue":"5","key":"10.1016\/bs.ircmb.2021.02.010_bb0250","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1038\/sj.leu.2404588","article-title":"Comparison of whole blood vs purified blood granulocytes for the detection and quantitation of JAK2(V617F)","volume":"21","author":"Hermouet","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/bs.ircmb.2021.02.010_bb0255","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","article-title":"European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia","volume":"34","author":"Hochhaus","year":"2020","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/bs.ircmb.2021.02.010_bb0260","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1182\/blood-2006-04-017392","article-title":"Involvement of various hematopoietic-cell lineages by the JAK2V617F mutation in polycythemia vera","volume":"108","author":"Ishii","year":"2006","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.02.010_bb0265","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1016\/j.leukres.2011.04.012","article-title":"Novel multiplex beadbased assay with LNA-modified probes for detection of MPL exon 10 mutations","volume":"35","author":"Ivanova","year":"2011","journal-title":"Leuk. Res."},{"issue":"10","key":"10.1016\/bs.ircmb.2021.02.010_bb0270","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1002\/cncr.23427","article-title":"Molecular monitoring in chronic myeloid leukemia: response to tyrosine kinase inhibitors and prognostic implications","volume":"112","author":"Jabbour","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/bs.ircmb.2021.02.010_bb0275","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nature03546","article-title":"A unique clonal JAK2 mutationleading to constitutive signalling causespolycythaemia vera","volume":"434","author":"James","year":"2005","journal-title":"Nature"},{"issue":"12","key":"10.1016\/bs.ircmb.2021.02.010_bb0280","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1002\/ajh.23321","article-title":"The differences and correlations of BCR-ABL transcripts between peripheral blood and bone marrow assays are associated with the molecular responses in the bone marrow for chronic myelogenous leukemia","volume":"87","author":"Jiang","year":"2012","journal-title":"Am. J. Hematol."},{"issue":"1","key":"10.1016\/bs.ircmb.2021.02.010_bb0285","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.leukres.2014.11.019","article-title":"Evaluation of methods to detect CALR mutations in myeloproliferative neoplasms","volume":"39","author":"Jones","year":"2015","journal-title":"Leuk. Res."},{"issue":"10","key":"10.1016\/bs.ircmb.2021.02.010_bb0290","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1038\/leu.2013.219","volume":"27","author":"Jovanovic","year":"2013","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/bs.ircmb.2021.02.010_bb0295","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1182\/blood-2007-09-110189","article-title":"Monitoring the response and course of chronic myeloid leukemia in the modern era of BCR-ABL tyrosine kinase inhibitors: practical advice on the use and interpretation of monitoring methods","volume":"111","author":"Kantarjian","year":"2008","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.02.010_bb0300","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/ejh.13172","article-title":"Clinical implications of molecular markers in acute myeloid leukemia","volume":"102","author":"Kayser","year":"2019","journal-title":"Eur. J. Haematol."},{"issue":"11","key":"10.1016\/bs.ircmb.2021.02.010_bb0305","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1038\/ng.988","article-title":"The new date, new format, new goals and new sponsor of the archon genomics X PRIZE competition","volume":"43","author":"Kedes","year":"2011","journal-title":"Nat. Genet."},{"issue":"4","key":"10.1016\/bs.ircmb.2021.02.010_bb0310","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1111\/j.1365-2141.2008.07223.x","article-title":"Mutations in exon 12 of JAK2 are mainly found in JAK2 V617F-negative polycythaemia vera patients","volume":"142","author":"Kouroupi","year":"2008","journal-title":"Br. J. Haematol."},{"key":"10.1016\/bs.ircmb.2021.02.010_bb0315","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A gain-of-function mutationof JAK2 in myeloproliferative disorders","volume":"352","author":"Kralovics","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/bs.ircmb.2021.02.010_bb0320","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1002\/ajh.23672","article-title":"Sensitive KIT D816V mutation analysis of blood as a diagnostic test in mastocytosis","volume":"89","author":"Kristensen","year":"2014","journal-title":"Am. J. Hematol."},{"key":"10.1016\/bs.ircmb.2021.02.010_bb0325","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1182\/blood-2006-08-039909","article-title":"Monitoring of the JAK2-V617F mutation by highly sensitive quantitative real-time PCR after allogeneic stem cell transplantation in patients with myelofibrosis","volume":"109","author":"Kr\u00f6ger","year":"2007","journal-title":"Blood"},{"issue":"2","key":"10.1016\/bs.ircmb.2021.02.010_bb0330","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1007\/s11899-015-0256-3","article-title":"Next-generation sequencing-based panel testing for myeloid neoplasms","volume":"10","author":"Kuo","year":"2015","journal-title":"Curr. Hematol. Malig. Rep."},{"issue":"5","key":"10.1016\/bs.ircmb.2021.02.010_bb0335","first-page":"596","article-title":"The hypereosinophilic syndrome: fluorescence in situ hybridization detects the del(4)(q12)-FIP1L1\/PDGFRA but not genomic rearrangements of other tyrosine kinases","volume":"90","author":"La Starza","year":"2005","journal-title":"Haematologica"},{"key":"10.1016\/bs.ircmb.2021.02.010_bb0340","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1111\/j.1365-2141.2007.06497.x","article-title":"The JAK2 V617F mutation involves B- and T-lymphocyte lineages in a subgroup of patients with Philadelphia-chromosome negative chronic yeloproliferative disorders","volume":"136","author":"Larsen","year":"2007","journal-title":"Br. J. Haematol."},{"issue":"5","key":"10.1016\/bs.ircmb.2021.02.010_bb0345","doi-asserted-by":"crossref","first-page":"E128","DOI":"10.1002\/ajh.25065","article-title":"Mayo CALR mutation type classification guide using alpha helix propensity","volume":"93","author":"Lasho","year":"2018","journal-title":"Am. J. Hematol."},{"issue":"3","key":"10.1016\/bs.ircmb.2021.02.010_bb0350","doi-asserted-by":"crossref","first-page":"278","DOI":"10.2353\/jmoldx.2010.090177","article-title":"Detection of exon 12 mutations in the JAK2 gene: enhanced analytical sensitivity using clamped PCR and nucleotide sequencing [published correction appears in J Mol Diagn. 2010 Sep;12(5):730]","volume":"12","author":"Laughlin","year":"2010","journal-title":"J. Mol. Diagn."},{"key":"10.1016\/bs.ircmb.2021.02.010_bb0355","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1182\/blood.V68.5.996.996","article-title":"A prospective study of the value of bone marrow erythroid progenitor cultures in polycythemia","volume":"68","author":"Lemoine","year":"1986","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.02.010_bb0360","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","article-title":"Activating mutation in thetyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia,and myeloid metaplasia with myelofibrosis","volume":"7","author":"Levine","year":"2005","journal-title":"Cancer Cell"},{"issue":"7","key":"10.1016\/bs.ircmb.2021.02.010_bb0365","doi-asserted-by":"crossref","first-page":"3863","DOI":"10.1182\/blood-2007-09-111971","article-title":"Clonal heterogeneity in polycythemia vera patients with JAK2 exon12 and JAK2-V617F mutations","volume":"111","author":"Li","year":"2008","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.02.010_bb0370","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1007\/s00277-018-3451-1","article-title":"A comparison of qPCR and ddPCR used for quantification of the JAK2 V617F allele burden in Ph negative MPNs","volume":"97","author":"Link-Lenczowska","year":"2018","journal-title":"Ann. Hematol."},{"issue":"6","key":"10.1016\/bs.ircmb.2021.02.010_bb0375","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1182\/blood-2006-01-013540","article-title":"The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera","volume":"108","author":"Lippert","year":"2006","journal-title":"Blood"},{"issue":"1","key":"10.1016\/bs.ircmb.2021.02.010_bb0380","doi-asserted-by":"crossref","first-page":"38","DOI":"10.3324\/haematol.13486","article-title":"Concordance of assays designed for the quantification of JAK2V617F: a multicenter study","volume":"94","author":"Lippert","year":"2009","journal-title":"Haematologica"},{"issue":"14","key":"10.1016\/bs.ircmb.2021.02.010_bb0385","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1182\/blood-2013-11-537167","article-title":"Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms","volume":"123","author":"Lundberg","year":"2014","journal-title":"Blood"},{"issue":"1","key":"10.1016\/bs.ircmb.2021.02.010_bb0390","doi-asserted-by":"crossref","first-page":"49","DOI":"10.2353\/jmoldx.2009.080114","article-title":"Mutation profile of JAK2 transcripts in patients with chronic myeloproliferative neoplasias","volume":"11","author":"Ma","year":"2009","journal-title":"J. Mol. Diagn."},{"key":"10.1016\/bs.ircmb.2021.02.010_bb0395","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1309\/AJCPXPA83MVCTSOQ","article-title":"Development and validation of CALR mutation testing for clinical diagnosis","volume":"144","author":"Maier","year":"2015","journal-title":"Am. J. Clin. Pathol."},{"issue":"1","key":"10.1016\/bs.ircmb.2021.02.010_bb0400","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jmoldx.2018.08.012","article-title":"Optimized digital droplet PCR for BCR-ABL","volume":"21","author":"Maier","year":"2019","journal-title":"J. Mol. Diagn."},{"key":"10.1016\/bs.ircmb.2021.02.010_bb0405","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jmoldx.2015.07.007","article-title":"Quantification of the mutant CALR allelic burden by digital PCR: application to minimal residual disease evaluation after bone marrow transplantation","volume":"18","author":"Mansier","year":"2016","journal-title":"J. Mol. Diagn."},{"issue":"8","key":"10.1016\/bs.ircmb.2021.02.010_bb0410","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.3109\/10428194.2015.1116122","article-title":"JAK2V617F and CALR double mutations are more frequently encountered in patients with low JAK2V617F allelic burdens","volume":"57","author":"Mansier","year":"2016","journal-title":"Leuk. Lymphoma"},{"issue":"12","key":"10.1016\/bs.ircmb.2021.02.010_bb0415","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.3324\/haematol.12011","article-title":"JAK2 exon 12 mutations in polycythemia vera or idiopathic erythrocytosis","volume":"92","author":"Mart\u00ednez-Avil\u00e9s","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/bs.ircmb.2021.02.010_bb756","unstructured":"McGowan-Jordan, J., Simons, A., Schmid, M., International Standing Committee on Human Cytogenomic Nomenclature, ISCN : an international system for human cytogenomic nomenclature (2016), Basel ; New York : Karger, [2016]. NLM ID: 101678834 [Book]"},{"key":"10.1016\/bs.ircmb.2021.02.010_bb0420","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1309\/AJCP5LA2LDDNQNNC","article-title":"Clinical validation of a multipurpose assay for detection and genotyping of CALR mutations in myeloproliferative neoplasms","volume":"144","author":"Mehrotra","year":"2015","journal-title":"Am. J. Clin. Pathol."},{"issue":"1","key":"10.1016\/bs.ircmb.2021.02.010_bb0425","doi-asserted-by":"crossref","first-page":"58","DOI":"10.2353\/jmoldx.2010.090068","article-title":"Design and evaluation of a real-time PCR assay for quantification of JAK2 V617F and wild-type JAK2 transcript levels in the clinical laboratory","volume":"12","author":"Merker","year":"2010","journal-title":"J. Mol. Diagn."},{"issue":"3","key":"10.1016\/bs.ircmb.2021.02.010_bb0430","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1182\/blood-2015-07-661835","article-title":"Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms","volume":"127","author":"Milosevic Feenstra","year":"2016","journal-title":"Blood"},{"issue":"11","key":"10.1016\/bs.ircmb.2021.02.010_bb0435","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1002\/ajh.23309","article-title":"Clinical significance of genetic aberrations in secondary acute myeloid leukemia","volume":"87","author":"Milosevic","year":"2012","journal-title":"Am. J. Hematol."},{"issue":"1","key":"10.1016\/bs.ircmb.2021.02.010_bb0440","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1093\/ajcp\/112.1.93","article-title":"Clonality analysis using X-chromosome inactivation at the human androgen receptor gene (Humara). Evaluation of large cohorts of patients with chronic myeloproliferative diseases, secondary neutrophilia, and reactive thrombocytosis","volume":"112","author":"Mitterbauer","year":"1999","journal-title":"Am. J. Clin. Pathol."},{"issue":"11","key":"10.1016\/bs.ircmb.2021.02.010_bb0445","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1080\/14737159.2017.1383156","article-title":"Diagnostic and prognostic cytogenetics of chronic myeloid leukaemia: an update","volume":"17","author":"Molica","year":"2017","journal-title":"Expert Rev. Mol. Diagn."},{"key":"10.1016\/bs.ircmb.2021.02.010_bb0450","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/0165-4608(85)90193-1","article-title":"An evaluation of high-resolution chromosome banding of hematologic cells by methotrexate synchronization and thymidine release","volume":"14","author":"Morris","year":"1985","journal-title":"Cancer Genet. Cytogenet."},{"key":"10.1016\/bs.ircmb.2021.02.010_bb0455","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1111\/ijlh.12484","article-title":"Validation of a molecular diagnostic assay for CALR exon 9 indels in myeloproliferative neoplasms: identification of coexisting JAK2 and CALR mutations and a novel 9 bp deletion in CALR","volume":"38","author":"Murugesan","year":"2016","journal-title":"Int. J. Lab. Hematol."},{"key":"10.1016\/bs.ircmb.2021.02.010_bb0460","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1312542","article-title":"Somatic CALR mutations inmyeloproliferative neoplasms with nonmutated JAK2","volume":"369","author":"Nangalia","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/bs.ircmb.2021.02.010_bb0465","doi-asserted-by":"crossref","first-page":"e438","DOI":"10.3324\/haematol.2015.129510","article-title":"DNMT3A mutations occur early or late in patients with myeloproliferative neoplasms and mutation order influences phenotype","volume":"100","author":"Nangalia","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/bs.ircmb.2021.02.010_bb0470","first-page":"85","article-title":"Chromosome studies on normal and leukemic human leukocytes","volume":"25","author":"Nowell","year":"1960","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/bs.ircmb.2021.02.010_bb0475","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.exphem.2006.11.012","article-title":"Polycythemia vera is not initiated by JAK2V617F mutation","volume":"35","author":"Nussenzveig","year":"2007","journal-title":"Exp. Hematol."},{"key":"10.1016\/bs.ircmb.2021.02.010_bb0480","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMoa1412098","article-title":"Effect of mutation order on myeloproliferative neoplasms","volume":"372","author":"Ortmann","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/bs.ircmb.2021.02.010_bb0485","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.6004\/jnccn.2016.0162","article-title":"NCCN guidelines insights: chronic myeloid leukemia, version 1.2017","volume":"14","author":"Pallera","year":"2016","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"10.1016\/bs.ircmb.2021.02.010_bb0490","doi-asserted-by":"crossref","first-page":"435","DOI":"10.2353\/jmoldx.2008.080015","article-title":"A sensitivedetection method for MPLW515L or MPLW515K mutation inchronic myeloproliferative disorders with locked nucleic acidmodifiedprobes and real-time polymerase chain reaction","volume":"10","author":"Pancrazzi","year":"2008","journal-title":"J. Mol. Diagn."},{"key":"10.1016\/bs.ircmb.2021.02.010_bb0495","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1159\/000085561","article-title":"Systemic mastocytosis: bone marrow pathology, classification, and current therapies","volume":"114","author":"Pardanani","year":"2005","journal-title":"Acta Haematol."},{"issue":"9","key":"10.1016\/bs.ircmb.2021.02.010_bb0500","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1038\/sj.leu.2404810","article-title":"Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera","volume":"21","author":"Pardanani","year":"2007","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/bs.ircmb.2021.02.010_bb0505","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1038\/leu.2010.163","article-title":"LNK mutation studies in blast-phase myeloproliferative neoplasms, and in chronic-phase disease with TET2, IDH, JAK2 or MPL mutations","volume":"24","author":"Pardanani","year":"2010","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/bs.ircmb.2021.02.010_bb0510","doi-asserted-by":"crossref","first-page":"233","DOI":"10.3343\/alm.2015.35.2.233","article-title":"Incidence, clinical features, and prognostic impact of CALR exon 9 mutations in essential thrombocythemia and primary myelofibrosis: an experience of a single tertiary hospital in Korea","volume":"35","author":"Park","year":"2015","journal-title":"Ann. Lab. Med."},{"issue":"1","key":"10.1016\/bs.ircmb.2021.02.010_bb0515","doi-asserted-by":"crossref","first-page":"17","DOI":"10.5045\/br.2020.55.1.17","article-title":"Characteristics of DNMT3A mutations in acute myeloid leukemia","volume":"55","author":"Park","year":"2020","journal-title":"Blood Res."},{"issue":"9","key":"10.1016\/bs.ircmb.2021.02.010_bb0520","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1038\/leu.2010.148","article-title":"A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications","volume":"24","author":"Passamonti","year":"2010","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/bs.ircmb.2021.02.010_bb0525","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1097\/MOH.0000000000000218","article-title":"New molecular genetics in the diagnosis and treatment of myeloproliferative neoplasms","volume":"23","author":"Passamonti","year":"2016","journal-title":"Curr. Opin. Hematol."},{"issue":"12","key":"10.1016\/bs.ircmb.2021.02.010_bb0530","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.3324\/haematol.11643","article-title":"The frequency of JAK2 exon 12 mutations in idiopathic erythrocytosis patients with low serum erythropoietin levels","volume":"92","author":"Percy","year":"2007","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/bs.ircmb.2021.02.010_bb0535","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1182\/blood-2007-07-101576","article-title":"Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders","volume":"111","author":"Pietra","year":"2008","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.02.010_bb0540","doi-asserted-by":"crossref","first-page":"607","DOI":"10.3324\/haematol.2010.034793","article-title":"Deep sequencing reveals double mutations in cis of MPL exon 10 in myeloproliferative neoplasms","volume":"96","author":"Pietra","year":"2011","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/bs.ircmb.2021.02.010_bb0545","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/leu.2015.277","article-title":"Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms","volume":"30","author":"Pietra","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/bs.ircmb.2021.02.010_bb0550","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1056\/NEJM197406132902419","article-title":"Bone-marrow responses in polycythemia vera","volume":"290","author":"Prchal","year":"1974","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/bs.ircmb.2021.02.010_bb0555","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1002\/stem.5530110613","article-title":"A novel clonality assay based on transcriptional analysis of the active X chromosome","volume":"11","author":"Prchal","year":"1993","journal-title":"Stem Cells"},{"issue":"6","key":"10.1016\/bs.ircmb.2021.02.010_bb0560","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1182\/blood-2016-10-695973","article-title":"Myeloid neoplasms with eosinophilia","volume":"129","author":"Reiter","year":"2017","journal-title":"Blood"},{"issue":"21","key":"10.1016\/bs.ircmb.2021.02.010_bb0565","doi-asserted-by":"crossref","first-page":"3070","DOI":"10.1182\/bloodadvances.2018020206","article-title":"When to obtain genomic data in acute myeloid leukemia (AML) and which mutations matter","volume":"2","author":"Roloff","year":"2018","journal-title":"Blood Adv."},{"issue":"67","key":"10.1016\/bs.ircmb.2021.02.010_bb0570","first-page":"481","article-title":"Molecular alterations underlying eosinophilic and mast cell malignancies","volume":"12","author":"Sadrzadeh","year":"2011","journal-title":"Discov. Med."},{"key":"10.1016\/bs.ircmb.2021.02.010_bb0575","doi-asserted-by":"crossref","first-page":"141","DOI":"10.3324\/haematol.13224","article-title":"Characterization of 35 new cases with four different MPLW515 mutations and essential thrombocytosis or primary myelofibrosis","volume":"94","author":"Schnittger","year":"2009","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/bs.ircmb.2021.02.010_bb0580","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/sj.leu.2402329","article-title":"Comparison of chromosome banding analysis, interphase-and hypermetaphase-FISH, qualitative and quantitative PCR for diagnosis and for follow-up in chronic myeloid leukemia: a study on 350 cases","volume":"16","author":"Schoch","year":"2002","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/bs.ircmb.2021.02.010_bb0585","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.bbrc.2005.08.111","article-title":"Signalling hypoxia by HIF hydroxylases","volume":"338","author":"Schofield","year":"2005","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"5","key":"10.1016\/bs.ircmb.2021.02.010_bb0590","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1056\/NEJMoa065202","article-title":"JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis","volume":"356","author":"Scott","year":"2007","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/bs.ircmb.2021.02.010_bb0595","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1182\/blood-2009-05-189985","article-title":"Involvement of oxygen-sensing pathways in physiologic and pathologic erythropoiesis","volume":"114","author":"Semenza","year":"2009","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.02.010_bb0600","series-title":"An International System of Human Cytogenetic Nomenclature","author":"Shaver","year":"2009"},{"issue":"20","key":"10.1016\/bs.ircmb.2021.02.010_bb0605","doi-asserted-by":"crossref","first-page":"5593","DOI":"10.1182\/blood-2011-03-343988","article-title":"Gene mutation patterns and their prognostic impact in a cohort of 1185 patients with acute myeloid leukemia","volume":"118","author":"Shen","year":"2011","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.02.010_bb0610","first-page":"288","article-title":"Prediction of clinical course in patients with idiopathic erythrocytosis by endogenous erythroid colony assay but not by serum erythropoietin levels","volume":"25","author":"Shih","year":"1997","journal-title":"Exp. Hematol."},{"key":"10.1016\/bs.ircmb.2021.02.010_bb0615","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1046\/j.1365-2362.1998.00331.x","article-title":"In vitro culture growth of erythroid progenitors and serum erythropoietin assay in the differential diagnosis of polycythaemia","volume":"28","author":"Shih","year":"1998","journal-title":"Eur. J. Clin. Invest."},{"issue":"1","key":"10.1016\/bs.ircmb.2021.02.010_bb0620","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1182\/asheducation-2018.1.127","article-title":"The new tool \u201cKIT\u201d in advanced systemic mastocytosis","volume":"2018","author":"Shomali","year":"2018","journal-title":"Hematology Am. Soc. Hematol. Educ. Program"},{"issue":"2","key":"10.1016\/bs.ircmb.2021.02.010_bb0625","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.leukres.2010.06.017","article-title":"JAK2(V617F) allele burden in polycythemia vera correlates with grade of myelofibrosis, but is not substantially affected by therapy","volume":"35","author":"Silver","year":"2011","journal-title":"Leuk. Res."},{"issue":"5","key":"10.1016\/bs.ircmb.2021.02.010_bb0630","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1182\/blood-2010-12-326405","article-title":"BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet","volume":"118","author":"Soverini","year":"2011","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.02.010_bb0635","author":"Specimen Considerations For Individuals With Hematologic Disease"},{"issue":"5","key":"10.1016\/bs.ircmb.2021.02.010_bb0640","first-page":"1099","article-title":"Quantitative real-time RT-PCR monitoring of BCR-ABL in chronic myelogenous leukemia shows lack of agreement in blood and bone marrow samples","volume":"28","author":"Stock","year":"2006","journal-title":"Int. J. Oncol."},{"key":"10.1016\/bs.ircmb.2021.02.010_bb0645","series-title":"Cancer Cytogenetics: Methods and Protocols (Methods in Molecular Biology)","volume":"220","author":"Swansbury","year":"2012"},{"issue":"12","key":"10.1016\/bs.ircmb.2021.02.010_bb0650","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1038\/leu.2015.249","article-title":"Presence of polyclonal hematopoiesis in females with Ph-negative myeloproliferative neoplasms","volume":"29","author":"Swierczek","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/bs.ircmb.2021.02.010_bb0655","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/nrclinonc.2014.16","article-title":"Genetics: CALR mutations and a new diagnostic algorithm for MPN","volume":"11","author":"Tefferi","year":"2014","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"7","key":"10.1016\/bs.ircmb.2021.02.010_bb0660","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1038\/leu.2014.57","article-title":"CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients","volume":"28","author":"Tefferi","year":"2014","journal-title":"Leukemia"},{"issue":"15","key":"10.1016\/bs.ircmb.2021.02.010_bb0665","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1182\/blood-2014-07-588426","article-title":"The prognostic advantage of calreticulin mutations in myelofibrosis might be confined to type 1 or type 1-like CALR variants","volume":"124","author":"Tefferi","year":"2014","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.02.010_bb0670","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1038\/leu.2013.302","article-title":"Targeted cancer exome sequencing reveals recurrent mutation in myeloproliferative neoplasms","volume":"28","author":"Tenedini","year":"2014","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/bs.ircmb.2021.02.010_bb0675","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.jmoldx.2016.08.006","article-title":"Detection of CALR and MPL mutations in low allelic burden JAK2 V617F essential Thrombocythemia","volume":"19","author":"Usseglio","year":"2017","journal-title":"J. Mol. Diagn."},{"key":"10.1016\/bs.ircmb.2021.02.010_bb0680","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1182\/blood-2011-02-292102","article-title":"New mutations and pathogenesis of myeloproliferative neoplasms","volume":"118","author":"Vainchenker","year":"2011","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.02.010_bb0685","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1080\/10428190400010775","article-title":"Mastocytosis: pathology, genetics, and current options for therapy","volume":"46","author":"Valent","year":"2005","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/bs.ircmb.2021.02.010_bb0690","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1038\/sj.leu.2403313","article-title":"Clinical and molecular features of FIP1L1-PDFGRA (+) chronic eosinophilic leukemias","author":"Vandenberghe","year":"2004","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/bs.ircmb.2021.02.010_bb0695","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1038\/sj.leu.2404854","article-title":"Prospective identification of high-risk polycythemia vera patients based on JAK2(V617F) allele burden","volume":"21","author":"Vannucchi","year":"2007","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/bs.ircmb.2021.02.010_bb0700","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1182\/blood-2006-12-064287","article-title":"Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia","volume":"110","author":"Vannucchi","year":"2007","journal-title":"Blood"},{"issue":"9","key":"10.1016\/bs.ircmb.2021.02.010_bb0705","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1038\/leu.2013.119","article-title":"Mutations and prognosis in primary myelofibrosis","volume":"27","author":"Vannucchi","year":"2013","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/bs.ircmb.2021.02.010_bb0710","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/ijlh.12949","article-title":"Genetic variants of erythropoietin (EPO) and EPO receptor genes in familial erythrocytosis","volume":"41","author":"Vo\u010danec","year":"2019","journal-title":"Int. J. Lab. Hematol."},{"issue":"12","key":"10.1016\/bs.ircmb.2021.02.010_bb0715","doi-asserted-by":"crossref","first-page":"5510","DOI":"10.1073\/pnas.92.12.5510","article-title":"Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension","volume":"92","author":"Wang","year":"1995","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/bs.ircmb.2021.02.010_bb0720","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1007\/s00277-016-2623-0","article-title":"Sensitive and accurate quantification of JAK2 V617F mutation in chronic myeloproliferative neoplasms by droplet digital PCR","volume":"95","author":"Waterhouse","year":"2016","journal-title":"Ann. Hematol."},{"key":"10.1016\/bs.ircmb.2021.02.010_bb0725","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/0165-4608(83)90044-4","article-title":"Fluorodeoxyuridine synchronization of bone marrow cultures","volume":"8","author":"Webber","year":"1983","journal-title":"Cancer Genet. Cytogenet."},{"key":"10.1016\/bs.ircmb.2021.02.010_bb0730","unstructured":"WHO, 2016, WHO\/BS\/2016.2293 Collaborative study to evaluate the proposed WHO 1st International Reference Panel for Genomic JAK2 V617F : http:\/\/www.who.int\/biologicals\/ECBS_2016_BS2293_JAK2_WHO_reference_panel. pdf?ua=1."},{"key":"10.1016\/bs.ircmb.2021.02.010_bb0735","series-title":"WHO Expert Committee on Biological Standardization, Sixty-Seventh Report(WHO Technical Report Series ; No. 1004)","author":"WHO","year":"2017"},{"issue":"11","key":"10.1016\/bs.ircmb.2021.02.010_bb0740","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1016\/j.exphem.2007.08.010","article-title":"Phenotypic variations and new mutations in JAK2 V617F-negative polycythemia vera, erythrocytosis, and idiopathic myelofibrosis","volume":"35","author":"Williams","year":"2007","journal-title":"Exp. Hematol."},{"issue":"5","key":"10.1016\/bs.ircmb.2021.02.010_bb0745","first-page":"5139","article-title":"Advantages of digital PCR in the detection of low abundance BCR-ABL1 gene in patients with chronic myeloid leukemia","volume":"18","author":"Yan","year":"2019","journal-title":"Oncol. Lett."},{"key":"10.1016\/bs.ircmb.2021.02.010_bb0750","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1186\/1471-2407-13-206","article-title":"Quantitative threefold allele-specific PCR (QuanTAS-PCR) for highly sensitive JAK2V617F mutant allele detection","volume":"13","author":"Zapparoli","year":"2013","journal-title":"BMC Cancer"},{"key":"10.1016\/bs.ircmb.2021.02.010_bb0755","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.cca.2009.10.012","article-title":"Sensitive detection of MPLW515L\/K mutations by amplification refractory mutation system (ARMS)-PCR","volume":"411","author":"Zhuge","year":"2010","journal-title":"Clin. Chim. Acta"}],"container-title":["International Review of Cell and Molecular Biology","Cellular and Molecular Aspects of Myeloproliferative Neoplasms \u2013 Part B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1937644821000150?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1937644821000150?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T07:20:35Z","timestamp":1753341635000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1937644821000150"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"ISBN":["9780323899413"],"references-count":151,"URL":"https:\/\/doi.org\/10.1016\/bs.ircmb.2021.02.010","relation":{},"ISSN":["1937-6448"],"issn-type":[{"value":"1937-6448","type":"print"}],"subject":[],"published":{"date-parts":[[2022]]}}}